Short-Interval, Low-Dose [177Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma

Stuart More; Thurandie Naiker; Nihaad Jacobs; Ferdinand Oompie; Vikas Prasad

doi:10.1097/RLU.0000000000004612

Short-Interval, Low-Dose [¹⁷⁷Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma

Stuart More, Thurandie Naiker, Nihaad Jacobs, Ferdinand Oompie, Vikas Prasad

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [177Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [177Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.

Original language	English
Pages (from-to)	E217-E218
Journal	Clinical nuclear medicine
Volume	48
Issue number	5
DOIs	https://doi.org/10.1097/RLU.0000000000004612
State	Published - May 1 2023

Keywords

PET
PSMA
glioblastoma
therapy

Access to Document

10.1097/RLU.0000000000004612

Cite this

@article{701237a67eff4ac49e1f906eb6261014,

title = "Short-Interval, Low-Dose [177Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma",

abstract = "Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [177Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [177Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.",

keywords = "PET, PSMA, glioblastoma, therapy",

author = "Stuart More and Thurandie Naiker and Nihaad Jacobs and Ferdinand Oompie and Vikas Prasad",

year = "2023",

month = may,

day = "1",

doi = "10.1097/RLU.0000000000004612",

language = "English",

volume = "48",

pages = "E217--E218",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

number = "5",

}

TY - JOUR

T1 - Short-Interval, Low-Dose [177Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma

AU - More, Stuart

AU - Naiker, Thurandie

AU - Jacobs, Nihaad

AU - Oompie, Ferdinand

AU - Prasad, Vikas

PY - 2023/5/1

Y1 - 2023/5/1

N2 - Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [177Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [177Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.

AB - Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [177Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [177Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.

KW - PET

KW - PSMA

KW - glioblastoma

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85151900069&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000004612

DO - 10.1097/RLU.0000000000004612

M3 - Article

C2 - 36881610

AN - SCOPUS:85151900069

SN - 0363-9762

VL - 48

SP - E217-E218

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 5

ER -

Short-Interval, Low-Dose [¹⁷⁷Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this